97 related articles for article (PubMed ID: 16487703)
1. Discovery of novel hydroxy pyrazole based factor IXa inhibitor.
Vijaykumar D; Sprengeler PA; Shaghafi M; Spencer JR; Katz BA; Yu C; Rai R; Young WB; Schultz B; Janc J
Bioorg Med Chem Lett; 2006 May; 16(10):2796-9. PubMed ID: 16487703
[TBL] [Abstract][Full Text] [Related]
2. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
Smallheer JM; Alexander RS; Wang J; Wang S; Nakajima S; Rossi KA; Smallwood A; Barbera F; Burdick D; Luettgen JM; Knabb RM; Wexler RR; Jadhav PK
Bioorg Med Chem Lett; 2004 Nov; 14(21):5263-7. PubMed ID: 15454208
[TBL] [Abstract][Full Text] [Related]
3. 5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa.
Qiao JX; Cheng X; Modi DP; Rossi KA; Luettgen JM; Knabb RM; Jadhav PK; Wexler RR
Bioorg Med Chem Lett; 2005 Jan; 15(1):29-35. PubMed ID: 15582405
[TBL] [Abstract][Full Text] [Related]
4. 5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa.
Batt DG; Qiao JX; Modi DP; Houghton GC; Pierson DA; Rossi KA; Luettgen JM; Knabb RM; Jadhav PK; Wexler RR
Bioorg Med Chem Lett; 2004 Nov; 14(21):5269-73. PubMed ID: 15454209
[TBL] [Abstract][Full Text] [Related]
5. 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Pinto DJ; Orwat MJ; Quan ML; Han Q; Galemmo RA; Amparo E; Wells B; Ellis C; He MY; Alexander RS; Rossi KA; Smallwood A; Wong PC; Luettgen JM; Rendina AR; Knabb RM; Mersinger L; Kettner C; Bai S; He K; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2006 Aug; 16(15):4141-7. PubMed ID: 16730984
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
Varnes JG; Wacker DA; Pinto DJ; Orwat MJ; Theroff JP; Wells B; Galemo RA; Luettgen JM; Knabb RM; Bai S; He K; Lam PY; Wexler RR
Bioorg Med Chem Lett; 2008 Jan; 18(2):749-54. PubMed ID: 18054227
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.
Ngo JC; Huang M; Roth DA; Furie BC; Furie B
Structure; 2008 Apr; 16(4):597-606. PubMed ID: 18400180
[TBL] [Abstract][Full Text] [Related]
8. Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors.
Zbinden KG; Obst-Sander U; Hilpert K; Kühne H; Banner DW; Böhm HJ; Stahl M; Ackermann J; Alig L; Weber L; Wessel HP; Riederer MA; Tschopp TB; Lavé T
Bioorg Med Chem Lett; 2005 Dec; 15(23):5344-52. PubMed ID: 16213138
[TBL] [Abstract][Full Text] [Related]
9. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
Shi Y; Sitkoff D; Zhang J; Han W; Hu Z; Stein PD; Wang Y; Kennedy LJ; O'Connor SP; Ahmad S; Liu EC; Seiler SM; Lam PY; Robl JA; Macor JE; Atwal KS; Zahler R
Bioorg Med Chem Lett; 2007 Nov; 17(21):5952-8. PubMed ID: 17855089
[TBL] [Abstract][Full Text] [Related]
10. Discovery of hydroxy pyrimidine Factor IXa inhibitors.
Jayne CL; Andreani T; Chan TY; Chelliah MV; Clasby MC; Dwyer M; Eagen KA; Fried S; Greenlee WJ; Guo Z; Hawes B; Hruza A; Ingram R; Keertikar KM; Neelamkavil S; Reichert P; Xia Y; Chackalamannil S
Bioorg Med Chem Lett; 2020 Aug; 30(15):127279. PubMed ID: 32527459
[TBL] [Abstract][Full Text] [Related]
11. Rapid development of two factor IXa inhibitors from hit to lead.
Parker DL; Walsh S; Li B; Kim E; Sharipour A; Smith C; Chen YH; Berger R; Harper B; Zhang T; Park M; Shu M; Wu J; Xu J; Dewnani S; Sherer EC; Hruza A; Reichert P; Geissler W; Sonatore L; Ellsworth K; Balkovec J; Greenlee W; Wood HB
Bioorg Med Chem Lett; 2015 Jun; 25(11):2321-5. PubMed ID: 25937013
[TBL] [Abstract][Full Text] [Related]
12. Factor IXa inhibitors as novel anticoagulants.
Howard EL; Becker KC; Rusconi CP; Becker RC
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):722-7. PubMed ID: 17272750
[TBL] [Abstract][Full Text] [Related]
13. Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.
Young WB; Mordenti J; Torkelson S; Shrader WD; Kolesnikov A; Rai R; Liu L; Hu H; Leahy EM; Green MJ; Sprengeler PA; Katz BA; Yu C; Janc JW; Elrod KC; Marzec UM; Hanson SR
Bioorg Med Chem Lett; 2006 Apr; 16(7):2037-41. PubMed ID: 16412633
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase.
Graneto MJ; Kurumbail RG; Vazquez ML; Shieh HS; Pawlitz JL; Williams JM; Stallings WC; Geng L; Naraian AS; Koszyk FJ; Stealey MA; Xu XD; Weier RM; Hanson GJ; Mourey RJ; Compton RP; Mnich SJ; Anderson GD; Monahan JB; Devraj R
J Med Chem; 2007 Nov; 50(23):5712-9. PubMed ID: 17948975
[TBL] [Abstract][Full Text] [Related]
15. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors.
Sakurada I; Endo T; Hikita K; Hirabayashi T; Hosaka Y; Kato Y; Maeda Y; Matsumoto S; Mizuno T; Nagasue H; Nishimura T; Shimada S; Shinozaki M; Taguchi K; Takeuchi K; Yokoyama T; Hruza A; Reichert P; Zhang T; Wood HB; Nakao K; Furusako S
Bioorg Med Chem Lett; 2017 Jun; 27(11):2622-2628. PubMed ID: 28408226
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and molecular modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors.
Chimenti F; Bolasco A; Manna F; Secci D; Chimenti P; Granese A; Befani O; Turini P; Alcaro S; Ortuso F
Chem Biol Drug Des; 2006 Mar; 67(3):206-14. PubMed ID: 16611214
[TBL] [Abstract][Full Text] [Related]
18. Discovery of inhibitors of the channel-activating protease prostasin (CAP1/PRSS8) utilizing structure-based design.
Tully DC; Vidal A; Chatterjee AK; Williams JA; Roberts MJ; Petrassi HM; Spraggon G; Bursulaya B; Pacoma R; Shipway A; Schumacher AM; Danahay H; Harris JL
Bioorg Med Chem Lett; 2008 Nov; 18(22):5895-9. PubMed ID: 18752942
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.
Lin R; Chiu G; Yu Y; Connolly PJ; Li S; Lu Y; Adams M; Fuentes-Pesquera AR; Emanuel SL; Greenberger LM
Bioorg Med Chem Lett; 2007 Aug; 17(16):4557-61. PubMed ID: 17574416
[TBL] [Abstract][Full Text] [Related]
20. Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa.
Kochanny MJ; Adler M; Ewing J; Griedel BD; Ho E; Karanjawala R; Lee W; Lentz D; Liang AM; Morrissey MM; Phillips GB; Post J; Sacchi KL; Sakata ST; Subramanyam B; Vergona R; Walters J; White KA; Whitlow M; Ye B; Zhao Z; Shaw KJ
Bioorg Med Chem; 2007 Mar; 15(5):2127-46. PubMed ID: 17227710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
